[go: up one dir, main page]

AR112282A1 - Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica - Google Patents

Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica

Info

Publication number
AR112282A1
AR112282A1 ARP180102032A AR112282A1 AR 112282 A1 AR112282 A1 AR 112282A1 AR P180102032 A ARP180102032 A AR P180102032A AR 112282 A1 AR112282 A1 AR 112282A1
Authority
AR
Argentina
Prior art keywords
cabotegravir
rilpivirine
prepare
combination
pharmaceutical form
Prior art date
Application number
Other languages
English (en)
Inventor
William R Spreen
Andrew Spaltenstein
Peter Williams
Herta Crauweis
David Margolis
Original Assignee
Viiv Healthcare Co
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Janssen Sciences Ireland Uc filed Critical Viiv Healthcare Co
Publication of AR112282A1 publication Critical patent/AR112282A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Uso de la combinación de cabotegravir o una de sus sales farmacéuticamente aceptables y rilpivirina o una de sus sales farmacéuticamente aceptables para preparar una forma farmacéutica para el tratamiento de VIH que comprende la administración intramuscular una vez cada 4 semanas o con menos frecuencia.
ARP180102032 2017-07-21 2018-07-19 Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica AR112282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762535302P 2017-07-21 2017-07-21

Publications (1)

Publication Number Publication Date
AR112282A1 true AR112282A1 (es) 2019-10-09

Family

ID=63080239

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102032 AR112282A1 (es) 2017-07-21 2018-07-19 Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica

Country Status (12)

Country Link
US (4) US11564921B2 (es)
EP (1) EP3654980A1 (es)
JP (2) JP7384783B2 (es)
KR (1) KR20200031658A (es)
CN (2) CN117298114A (es)
AR (1) AR112282A1 (es)
AU (2) AU2018304591A1 (es)
CL (1) CL2020000176A1 (es)
IL (1) IL271987A (es)
MX (1) MX2020000790A (es)
TW (1) TWI860978B (es)
WO (1) WO2019016732A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7384783B2 (ja) * 2017-07-21 2023-11-21 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
KR20220074880A (ko) * 2019-10-01 2022-06-03 비이브 헬쓰케어 컴퍼니 카보테그라비르 및 릴피비린에 의해 hiv를 치료하는 방법
JP2023532717A (ja) * 2020-07-02 2023-07-31 ヴィーブ ヘルスケア カンパニー 長期作用型抗レトロウイルス剤を用いたｈｉｖウイルス寛解の達成方法
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
TNSN00027A1 (fr) 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease
BRPI0610030B8 (pt) 2005-04-28 2022-01-11 Glaxosmithkline Llc Composto, composição farmacêutica, e, uso de um composto
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
HK1209638A1 (en) 2012-12-14 2016-04-08 Glaxosmithkline Llc Pharmaceutical compositions
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
BR112017006005A2 (pt) 2014-09-26 2017-12-19 Glaxosmithkline Ip No 2 Ltd composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
JP7384783B2 (ja) * 2017-07-21 2023-11-21 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン

Also Published As

Publication number Publication date
AU2018304591A1 (en) 2020-03-05
WO2019016732A1 (en) 2019-01-24
US12178815B2 (en) 2024-12-31
RU2020102304A (ru) 2021-08-23
JP2020528063A (ja) 2020-09-17
JP7663660B2 (ja) 2025-04-16
CA3070319A1 (en) 2019-01-24
TW201919630A (zh) 2019-06-01
JP2024020333A (ja) 2024-02-14
US11564921B2 (en) 2023-01-31
CN111107850A (zh) 2020-05-05
MX2020000790A (es) 2020-11-11
TWI860978B (zh) 2024-11-11
US20240350486A1 (en) 2024-10-24
KR20200031658A (ko) 2020-03-24
US20230120910A1 (en) 2023-04-20
CL2020000176A1 (es) 2020-06-12
EP3654980A1 (en) 2020-05-27
CN117298114A (zh) 2023-12-29
AU2021261965A1 (en) 2021-12-02
RU2020102304A3 (es) 2022-03-11
US20250114352A1 (en) 2025-04-10
IL271987A (en) 2020-02-27
US20200147079A1 (en) 2020-05-14
JP7384783B2 (ja) 2023-11-21

Similar Documents

Publication Publication Date Title
SV2018005778A (es) Derivados aromaticos de sulfonamida
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MX2017001512A (es) Compuestos activos hacia bromodominios.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
ECSP17084331A (es) Formulaciones farmacéuticas
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
AR112282A1 (es) Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica
CL2017001001A1 (es) Derivados de carbazaol
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
AR114030A1 (es) Triterpenos pentacíclicos en el tratamiento de una patología oral-dental
CR20160581A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor

Legal Events

Date Code Title Description
FB Suspension of granting procedure